-
Missing passengers likely went down with sunken ferry: N.Cyprus official
-
George Clooney says US run by 'least qualified people'
-
Premier League clubs splash cash to smash transfer record
-
China's Xi urges against Mideast interference in rare Egypt visit
-
Melting glaciers an 'immediate' climate risk: author of UN report
-
Venice to roll out red carpet for 'lucky' Clooney on opening night
-
Folarin Balogun's move to Everton collapses
-
'Humiliated' Aubameyang quits Gabon national team
-
Pacific islands to face food shortages over global warming: scientists
-
France sees limited economic hit from drought, heatwaves
-
Venice jury head Maggie Gyllenhaal questions lack of women directors
-
Bus crash in Egypt's Sinai kills 22, including 10 Jordanians
-
Stocks drop, bond yields rally on Mideast flare-up
-
UN says world must navigate 'reality' of 1.5C overshoot
-
China expands Egypt investments in first Xi visit in a decade
-
Taliban govt defends ban on protest, citing Islamic law
-
Messi departure leaves Argentina facing rebuild after golden era
-
10 missing as Turkish cargo ship sinks after collision off Istanbul
-
Ourbit SuperCEX Launches "Cosmic Wheel Season 3. Oracle Realm" on September 2 with 3M USDT Prize Pool
-
easyMarkets Expands Commodity Offering with 24/7 Gold, Silver and Oil Trading
-
Ebola death toll passes 3,000 in DR Congo: official data
-
Australia defends Pacific climate meeting despite doubts on attendance
-
Hong Kong democracy activist Wong pleads guilty to foreign collusion
-
Iran attacks US sites after American strikes, wedding deaths
-
World record prize winner Romantic Warrior retires from horse racing
-
Stocks drop, yields at three-decade highs on Mideast flare-up
-
5,000 US sailors arrive in Thailand after months at sea
-
EU summons Russian envoy, eyes sanctions after Germany drone 'attack'
-
Joshua Wong, Hong Kong's pro-democracy poster child
-
Stocks drop as yields and oil prices spike on Mideast flare-up
-
Nepal tunnel rescuers seek trapped workers but hit dead ends
-
Cricketers to get best rooms at Asian Games, says Japan chief
-
Zverev wins wild five-setter, Rybakina and Gauff ease through at US Open
-
Zverev out-lasts Sonego in wild five-setter to advance at US Open
-
US energy secretary arrives in Venezuela to discuss oil deal
-
Amid war, Ukrainian soldiers celebrate love at ritual wedding
-
Meloni government becomes Italy's longest-lasting
-
Venice to roll out red carpet for Clooney on opening night
-
Funerals in Nepal for missing, a week after deadly floods
-
Hong Kong democracy activist Wong pleads guilty to foreign collusion: AFP
-
US aircraft carrier arrives in Thailand after months at sea
-
Stocks sink, yields at multi-decade highs and oil spikes on Mideast flare-up
-
US aircraft carrier approaches Thai port after months at sea
-
US defends Trump Venezuela oil deal as energy secretary lands in Caracas
-
Nepal's young PM faces gravest test after flood catastrophe
-
Jubilant Monfils celebrates birthday with US Open win
-
What rainbow? LGBTQ Indonesians on edge as hostility mounts
-
The Japanese idealist behind the last deradicalisation NGO in Somalia
-
O'Connor eyes Wallabies World Cup swansong after Force return
-
Rybakina, Gauff advance as Zverev launches US Open campaign
Exousia Pro Will Launch a Web Series with Our New Consultant
Dr. Marvin Hausman is joining Exousia Pro as a Consultant and will host a weekly series.
ORLANDO, FL / ACCESS Newswire / April 30, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of cancer and other diseases, is launching a weekly web series titled "Ask Dr. Hausman."
Our chief science officer, Dr. Marvin Hausman, will join Exousia Pro as a consultant; his contract is being finalized now. Dr. Hausman was instrumental in creating Exousia AI and establishing the Glioblastoma study with UCF, and will assist Exousia Pro in advancing therapies using our plant-based exosomes. Exousia Pro will launch a new web series, "Ask Dr. Hausman." Shareholders will be able to email questions that Dr. Hausman will answer weekly. Dr. Hausman will also share updates on various studies conducted, our FDA submissions, and future IND trials.
Matt Dwyer, our President, stated, "Exousia Pro is very fortunate to have Dr. Hausman working with us. His rolodex of scientific and financial professionals in the biotech world is priceless. We believe that Dr. Hausman can open doors for Exousia Pro that we could never do. I met Marvin about 1 year ago and have established a strong relationship with him, and I look forward to working closely with him in advancing Exousia Pro."
About Us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
[email protected]
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
A.O.Scott--AT